Physician and patient preferences for dosing options in migraine prevention.
Adolescent
Adult
Aged
Aged, 80 and over
Analgesics
/ administration & dosage
Biological Products
/ administration & dosage
Chronic Disease
Drug Administration Schedule
Female
Humans
Male
Medication Adherence
/ psychology
Middle Aged
Migraine Disorders
/ diagnosis
Patient Preference
/ psychology
Physician-Patient Relations
Physicians
/ psychology
Surveys and Questionnaires
Young Adult
CGRP antibody
Dosing flexibility
Dosing preference
Migraine prevention
Monthly dosing
Quarterly dosing
Therapy adherence
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
09 May 2019
09 May 2019
Historique:
received:
14
02
2019
accepted:
16
04
2019
entrez:
11
5
2019
pubmed:
11
5
2019
medline:
19
7
2019
Statut:
epublish
Résumé
Adherence to a therapy, though a key factor for successful treatment, is low among patients with chronic conditions such as migraine. Dose frequency plays a major role in adherence. This study evaluated the impact of having flexible dosing options on acceptance of and adherence to a new migraine preventive therapy class among adults with migraine. In this observational study, two 20-min online surveys were completed: one by physicians currently treating adult patients with migraine and the other by adults with migraine. Both surveys presented the participants with three scenarios: 1) only monthly, 2) only quarterly, and 3) both dosing options of the new medication are available. Physicians estimated the proportion of their migraine patients who would receive the new medication in each scenario. Patients were asked about their dosing preference when either or both options are available. Respondents were asked to rate the likelihood of their acceptance of and adherence to the therapy. 400 physicians and 417 US adults with migraine completed the surveys. The availability of both dosing options yielded a significant increase in the proportion of patients expected to receive the new medication. The overall proportion of patients favoring monthly dosing (35%) was similar to the proportion favoring quarterly dosing (40%). Among those who preferred monthly dosing (n = 147), a greater proportion indicated they are more likely to fill the prescription (77% vs 56%, P < 0.05) and remain adherent (80% vs 57%, P < 0.05) when only monthly is available versus when only quarterly is available. Similarly, among those who preferred quarterly dosing (n = 166), a greater proportion indicated they are likely to fill (63% vs 55%, P < 0.05) and remain adherent (62% vs 54%, P < 0.05) when only quarterly is available compared with when only monthly is available. Physicians anticipated that the proportion of patients to receive the new medication would increase when both dosing options are available. Patients stated that they are more likely to fill the prescription and adhere to the new therapy when their preferred dosing regimen is available.
Sections du résumé
BACKGROUND
BACKGROUND
Adherence to a therapy, though a key factor for successful treatment, is low among patients with chronic conditions such as migraine. Dose frequency plays a major role in adherence. This study evaluated the impact of having flexible dosing options on acceptance of and adherence to a new migraine preventive therapy class among adults with migraine.
METHODS
METHODS
In this observational study, two 20-min online surveys were completed: one by physicians currently treating adult patients with migraine and the other by adults with migraine. Both surveys presented the participants with three scenarios: 1) only monthly, 2) only quarterly, and 3) both dosing options of the new medication are available. Physicians estimated the proportion of their migraine patients who would receive the new medication in each scenario. Patients were asked about their dosing preference when either or both options are available. Respondents were asked to rate the likelihood of their acceptance of and adherence to the therapy.
RESULTS
RESULTS
400 physicians and 417 US adults with migraine completed the surveys. The availability of both dosing options yielded a significant increase in the proportion of patients expected to receive the new medication. The overall proportion of patients favoring monthly dosing (35%) was similar to the proportion favoring quarterly dosing (40%). Among those who preferred monthly dosing (n = 147), a greater proportion indicated they are more likely to fill the prescription (77% vs 56%, P < 0.05) and remain adherent (80% vs 57%, P < 0.05) when only monthly is available versus when only quarterly is available. Similarly, among those who preferred quarterly dosing (n = 166), a greater proportion indicated they are likely to fill (63% vs 55%, P < 0.05) and remain adherent (62% vs 54%, P < 0.05) when only quarterly is available compared with when only monthly is available.
CONCLUSIONS
CONCLUSIONS
Physicians anticipated that the proportion of patients to receive the new medication would increase when both dosing options are available. Patients stated that they are more likely to fill the prescription and adhere to the new therapy when their preferred dosing regimen is available.
Identifiants
pubmed: 31072307
doi: 10.1186/s10194-019-0998-8
pii: 10.1186/s10194-019-0998-8
pmc: PMC6734424
doi:
Substances chimiques
Analgesics
0
Biological Products
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Références
Headache. 2001 Jul-Aug;41(7):646-57
pubmed: 11554952
Clin Ther. 2001 Aug;23(8):1296-310
pubmed: 11558866
Clin Ther. 2003 Aug;25(8):2307-35; discussion 2306
pubmed: 14512137
Cephalalgia. 2005 Mar;25(3):165-78
pubmed: 15689191
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
BMJ. 2006 Jul 1;333(7557):15
pubmed: 16790458
Headache. 2007 Apr;47(4):540-5
pubmed: 17445103
Cephalalgia. 2007 Oct;27(10):1156-65
pubmed: 17784854
J Neurol. 2009 Apr;256(4):568-76
pubmed: 19444532
Eur J Neurol. 2011 Jan;18(1):69-77
pubmed: 20561039
Eur Neurol. 2011;65(2):59-67
pubmed: 21212677
J Vestib Res. 2011;21(6):305-14
pubmed: 22348935
Headache. 2013 Apr;53(4):644-55
pubmed: 23458496
Front Pharmacol. 2013 Jul 25;4:91
pubmed: 23898295
Cephalalgia. 2015 May;35(6):478-88
pubmed: 25164920
Lancet Neurol. 2015 Oct;14(10):1010-22
pubmed: 26376968
Cephalalgia. 2017 Apr;37(5):470-485
pubmed: 27837173
J Headache Pain. 2017 Oct 6;18(1):102
pubmed: 28986900
N Engl J Med. 2017 Nov 30;377(22):2113-2122
pubmed: 29171818
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679
JAMA. 2018 May 15;319(19):1999-2008
pubmed: 29800211
Cephalalgia. 2018 Jul;38(8):1442-1454
pubmed: 29848108
Neuropsychiatr Dis Treat. 2018 Jun 08;14:1475-1492
pubmed: 29922063
Am J Clin Nutr. 1996 Jun;63(6):884-90
pubmed: 8644682
Drugs. 1997 Dec;54(6):797-800
pubmed: 9421690